Interventional Cardiology and
Angiology

Prevention of Restenosis - Mercator and
Marcator Study, QUIET Trial, Trapidil, Probucol
- The rationale of Mercator or Marcator was that ACE inhibitors
are thought to preserve endothelial integrity and to prevent lipid
accumulation as well as to inhibit cellular growth and
proliferation of SMC (Powell et al.).
- Both studies showed that low dose or even high dose ACE
inhibition with cilazapril did not prevent restenosis.
- Reasons for the lack of effect: Dose relation?, time
relation?, alternative pathways of angiotensin II?, many other
factors!
- QUIET: The trial will evaluate the ability of quinapril to
reduce the rate of cardiac ischemic event and to slow or prevent
the development of coronary artery disease assessed by QCA.
- Trapidil: The results of three human trials showed that
trapidil is capable to reduce restenosis after PTCA by
40%-53%.
- Although there is a beneficial effect on restenosis, trapidil
has not received more attention!
- Probucol: The antioxidant probucol is effective in reducing
the rate of restenosis by 20% after balloon coronary
angioplasty.
Universitätsklinikum Charité - Medizinische Fakultät
der Humboldt-Universität zu Berlin, Campus Berlin-Buch
Franz-Volhard-Klinik
Wiltbergstraße 50, D - 13125 Berlin
Tel.: +49 30 9417 2996 - Fax: +49 30 9497 074
Letzte Änderung: 17.11.98 -
© 1998 - webmaster